Background-Molecular mechanisms underlying psychological sequelae of exposure to stressful experiences, such as Post-Traumatic Stress Disorder (PTSD) and depression, are not well understood.
Introduction
Exposure to stressful or traumatic life experiences increases risks of developing depressive disorders, anxiety disorders, or post-traumatic stress disorder (PTSD) (1) . Anxiety and depressive disorders rank at the top of disabling mental illnesses causing tremendous economic costs to society (2) . However, effectiveness of pharmacological treatments for anxiety and depressive disorders still remains rather limited with small effect sizes (3, 4) . To facilitate efforts in developing novel treatments for these disorders, better insights into molecular mechanisms underlying anxiety and depression are needed.
With the goal of elucidating molecular mechanisms underlying anxiety and depression after traumatic experiences, we used convergent evidence from both animal and human studies. We note that among susceptible individuals, PTSD and depression are often comorbid (PTSD&Dep) (5) . The shared symptoms and relatively high prevalence of PTSD and depression comorbidity suggest that examining their comorbidity in the aftermath of trauma may be a more powerful approach than examining either outcome alone. In addition, animal stress models leading to similar PTSD-like or depression-like behaviors can facilitate our efforts in uncovering their neurobiological mechanisms (6, 7) .
Methods

Animals
All experiments were performed on adult wild-type C57BL/6J mice obtained from Jackson Labs. Male and female mice were group-housed in a temperature-controlled vivarium, with ad libitum access to food and water. See detailed methods for ethics protocols. Female mice were used only when explicitly stated, otherwise only male mice were used. with current symptoms of comorbid PTSD and depression (PTSD&Dep) were defined as having PSS≥14 and BDI≥14. Controls were defined as not having either PTSD or depressive symptoms, as reflected by a PSS ≤7 and BDI ≤7, despite being exposed to trauma. See Supplementary Methods for rationale behind these cutoff scores. Of note, these participants were not part of a rigorously assessed clinical sample.
RNA was extracted from blood collected in the morning. All samples had RNA Integrity Number (RIN) ≥6. Raw probe intensities were generated on Illumina HumanHT-12 v3 or v4 BeadChip arrays. We performed normalization of probe intensities using the Supervised Normalization of Microarray algorithm (18) , removing the effects of batch and RIN. Association between mRNA level of a gene of interest and PTSD&Dep status was examined using multiple linear regression adjusting for gender, age, and population substructure.
Center for Health Discovery and Well Being (CHDWB) replication sample and gene expression profiles
The CHDWB project evaluated effectiveness of a health-and prevention-focused approach (19) . Anxiety symptoms were assessed with the GAD-7 scale (20), a well-validated and efficient tool for screening anxiety symptoms. A score of 5-9 on the GAD-7 indicates mild anxiety, 10-14 moderate, and 15-21 severe anxiety symptoms (20) . We categorized participants with GAD-7 scores of ≥ 5 as having anxiety symptoms and those with GAD-7 scores ≤1 as controls.
RNA was extracted from whole blood and all samples had RIN >7. Probe intensities were generated on Illumina HT12 v3 or v4 beadchip arrays. We performed normalization using the Supervised Normalization of Microarrays (18) . Human PPM1F microarrays from CHWDB are available at GEO #GSE61672.
PPM1F genotypes and principal components among GTP participants
DNA was extracted from saliva or blood, and genotyping was conducted using Illumina's HumanOmni1-Quad. Standard quality control of the genotyping was performed using PLINK (21) , removing individuals with >2% missing data and removing one in each pair of related individuals with an identity by descent proportion >0.12 (indicating cousins or a closer relation). We used principal component analysis to infer axes of ancestry and remove outlier subjects following methods previously described (22) . Association between PPM1F
Postmortem eQTL Analysis
Association between rs17759843 and brain mRNA level of PPM1F was provided by Brain Cloud, which has gene expression profiles from the dorsolateral prefrontal cortex of 269 subjects without neuropathological and neuropsychiatric diagnosis (25) .
Results
Behavior and gene expression profiles in Amygdala and mPFC of stressed mice
We performed transcriptome-wide differential expression analysis of genes in the Amygdala and mPFC in mice 6 and 8 days after immobilization (IMO) stress versus controls. We examined gene expression profiles in the Amygdala at 6 days and 8 days after IMO stress to determine if the long-term gene expression changes found at 6 days were also sustained at 8 days. Figures 1A-D show the heatmaps revealing differences in the gene expression in stressed versus control mice groups. Of the probes that were differentially expressed at unadjusted p<0.05 in the Amygdala, we used the following criteria to select probes for follow-up: a) probe differentially expressed at unadjusted p-value <0.05 at both 6 days and 8 days after stress; b) probe with >1.5 fold change between cases and controls; c) probe is expressed at moderate to high levels in the Amygdala (through search in the Allen Brain Atlas). Supplemental Table S1 lists the 24 probes that met these criteria. Of note, without adjusting for multiple testing, there is an increased risk of false positives. Therefore, we performed replication of these probes in different mouse cohorts to determine if they were differentially expressed between cases and controls using RT-PCR. Of these 24 probes, 21 had available primers for the RT-PCR replication ( Supplemental Table S2 ). Supplemental Table S3 lists the results of the PCR replication in the Amygdala. We found five probes whose altered mRNA levels were replicated with PCR; Ppm1f was one of them. Along with our replication studies, we showed that these gene expression changes, which occurred 6 to 8 days after IMO, may need an incubation period because no significant changes in gene expression were found 1 day after exposure to stress ( Supplemental Table S3 ). Interestingly, although Ppm1f is significantly regulated 6-8 days post-stress, it is not regulated in the Amygdala 30 minutes or 2 hours after fear conditioning (FC) nor in the mPFC 2 hours after FC (Supplemental Figure S2 ). Thus, Ppm1f appears to have a dynamic expression after stress in the brain. Moreover, only five of these genes were significantly regulated after stress -Hbp1, Ssbp4, Fbxl5, Ppm1f and Fhl1 -at three different time points: 6, 7 and 8 days after IMO ( Supplemental Table S3 ). Thus, we examined the expression of these five genes in human. Among them, only PPM1F was differentially expressed between cases with symptoms of PTSD&Dep versus controls ( Supplemental Table S4 ; more detailed description to follow).
We followed similar criteria to select probes with unadjusted p-value <0.05 from the mPFC transcriptome-wide differential analysis for further replication in a mouse microarray (more details in Supplemental Methods). See Supplemental Table S5 for the list of genes that survived the filtering criteria and were followed up with RT-PCR replication. The number of top-regulated genes within these microarrays and their overlap are represented in Figure 1E . Ppm1f was the only gene highly regulated in all the three mouse microarray conditions. Behaviorally, two groups of mice were exposed to IMO stress and 6 days later they were tested in the elevated plus maze (EPM, anxiety-like behavior) or the tail suspension test (TST, depressive-like behavior). The EPM results showed that stress reduced the time mice spent in the open arms ( Figure 1F top, t=4.597 df=14, p=0.0004). Moreover, the TST analysis revealed that stress increased the time mice spent in immobility ( Figure 1F down, f=2.280, df=7, p=0.0361).
Brain functions altered after acute stress, network analysis and predicted interactions with drugs
We performed bioinformatics analyses of the shared genes that had altered expression in the microarray. The list of the genes studied with DAVID are in Supplemental Tables S1 and S5 and Supplemental Figure S3 . We found that the top three functions altered in both the Amygdala and mPFC were phosphoproteins (including Ppm1f), alternative splicing, and splice variants ( Figure 2A) . A more detailed functional analysis with IPA showed the biological pathways that were most different between stress and control animals included cell morphology, gene expression, and cellular development ( Figure 2B ). Supplemental Figure S4 shows that PPM1F has direct relationships with the CaMK2 family and indirect relationships with brain-derived neurotrophic factor (BDNF), cAMP response elementbinding (CREB), extracellular signal-regulated kinase 1/2 (Erk 1/2) and (Mitogen-activated protein kinase kinase) Map2K 1/2.
Examine expression of the above five genes in comorbid PTSD & Depression
We next examined expression of the five genes identified to be significantly differentially regulated in mouse Amygdala after exposure to stress in 230 GTP human participants who were exposed to at least one traumatic experience. Their sociodemographic characteristics are presented in Supplemental Table S6 . Of these participants, 142 were cases with PTSD&Dep symptoms and 88 were controls with no PTSD and no depressive symptoms. Among these five genes, PPM1F (ILMN_2059535) was significantly associated with PTSD&Dep after adjusting for gender, age, and population substructure (β=0.135; p=0.005; Bonferroni adjusted p=0.025; N=230). Cases with PTSD&Dep symptoms had lower PPM1F expression than controls ( Figure 3A) . Notably, PPM1F is highly expressed in the brain in both mice and humans (Supplemental Figure S5 ).
PPM1F in anxiety in a replication sample
Given that PTSD patients present with anxiety symptoms, we examined blood mRNA of PPM1F (ILMN_2059535) in anxiety in the CHWDB cohort, which has 151 cases with anxiety symptoms and 165 controls (N=316). Their characteristics are presented in Supplemental Table S7 . We found that PPM1F was significantly down-regulated in patients with anxious symptomatology versus controls after adjusting for gender and ethnicity (p=0.044, N=316, Figure 3B , Supplemental Table S7 ), consistent with the association found in the GTP sample. 
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Association between PPM1F SNPs and PTSD&Dep
Having identified PPM1F mRNA expression level to be significantly associated with PTSD, depression and anxiety, we next investigated whether certain PPM1F SNPs influence this association. To this end, we examined the association between PPM1F SNPs and PTSD&Dep, and whether the identified significant SNPs influenced PPM1F expression level in blood and brain. In the GTP human dataset, there was a total of 14 tagging SNPs for PPM1F. Among these SNPs, rs17759843, located in the 3′UTR of PPM1F, was significantly associated with PTSD&Dep after adjusting for sex and 10 genetic principal components (OR=0.53; p=0.0046; permuted p=0.0463; N=2361; Figure 4 ). The minor allele of rs17759843 was associated with lower odds for comorbid PTSD&Dep (Figure 4 ). rs17759843 has a MAF of 0.018 and p-value for departure from HWE of 0.6 in the unaffected population and 1 in affected population.
PPM1F rs17759843 influences expression of PPM1F in human blood
Since we found rs17759843 significantly associated with PTSD&Dep, we examined whether this SNP is associated with human blood PPM1F mRNA level in 358 GTP participants. There was no significant association between this SNP and PPM1F mRNA level after adjusting for sex, age, and population substructure (p=0.635, N=358). However, when we looked at the Blood eQTL browser (24) of 5300 human samples, there was a highly significant association between rs17759843 and PPM1F (p=6.1 × 10 −25 , FDR=0.00; effect size Z-score = 10.31). Specifically, the minor allele of rs17759843 was associated with higher expression of PPM1F. This directionality is consistent with our genetic and gene expression findings in the GTP sample, in which the minor allele of rs17759843 was significantly associated with lower probability of having PTSD&Dep, and that controls had higher expression of PPM1F relative to that of PTSD&Dep cases. With a larger sample size and thus more power, we conclude that rs17759843 is indeed a blood cis-eQTL for PPM1F mRNA expression in humans.
rs17759843 influences expression of PPM1F in human brain
Since Ppm1f mRNA level was upregulated in the amygdala and downregulated in the mPFC of stressed mice, which is consistent with another published study (26) , we examined whether rs17759843 is associated with brain mRNA level of PPM1F in the publicly available BrainCloud dataset, which has human gene expression profiles of the prefrontal cortex. There was a total of three probes for PPM1F in this dataset. Of these, two probes had significant association with PPM1F: Probe 8896: p=0.0032, Bonferroni-adjusted p=0.0097;
and Probe 16009: p=0.0004, Bonferroni-adjusted p=0.0012. In sum, rs17759843 is significantly associated with PPM1F mRNA level in human prefrontal cortex.
CAMK2
Since PPM1F regulates calcium/calmodulin-dependent protein kinase 2 (CaMK2) in neuronal cells (27, 28) and fibroblasts (29), we examined blood mRNA level of CaMK2 in PTSD&Dep. After QC, the human dataset had three probes for CaMK2 (one for CaMK2D and two for CaMK2G; none for CaMK2A or CaMK2B). Of these three probes, the CaMK2G probe had significantly lower expression in cases with PTSD&Dep symptoms versus controls after adjusting for gender, age, and population substructure (β=0.072; p=0.0158; Bonferroni corrected p = 0.0474, N=230; Supplemental Figure S6A -B).
We analyzed Camk2g in the mouse brain because it was the CaMK2 isoform that was most significantly regulated in our human dataset. After stress Camk2g mRNA was marginally upregulated in the mouse amygdala 6 days after IMO (t=2.213, df=8, p=0.058, Supplemental Figure S6C ). However, Camk2g expression was not regulated in mouse amygdala 2 hours after FC in mice with or without a previous exposure to stress (Supplemental Figure S6D ).
Immunohistochemistry of Ppm1f and Camk2g
Ppm1f protein levels were upregulated in the Central amygdala (CeA), Basolateral amygdala (BLA), the summatory of CeA+BLA (Total Amygdala) and the mPFC in male mice 6 days after stress IMO (Supplemental Figure S7) . Moreover, Ppm1f levels in the BLA were also upregulated in female mice 6 days after IMO (Supplemental Figure S8 ). Camk2g levels were upregulated in the CeA, BLA, Total Amygdala and mPFC in male mice 6 days after IMO (Supplemental Figure S9 ). However, there were no changes in Camk2g levels 6 days after IMO in female mice (Supplemental Figure S10 ). Figure 5 shows that IMO enhances the colocalization of Ppm1f and Camk2g in the Prelimbic cortex (PrL) (t= −2.308, df=12, p=0.046), Total Amygdala (t= −2.598, df=24, p=0.017) and the mPFC in male mice (t= −2.814, df=41, p=0.008) ( Figure 5 ). See Figure 6 for representative images of these immunohistochemistry studies.
Corticosterone and Ppm1f
Vehicle or corticosterone was given 1 hour after IMO in male and female mice. 6 days later TST, EPM and mRNA levels were evaluated. In males, there was a significant increase in total immobility as measured by TST in IMO+Veh (t=−2.328, df=14, p=0.037, Figure 7A ) and IMO+CORT (t=−2.45, df=14, p=0.029, Figure 7B ) groups compared to Control+Veh group. In females, there was a significant increase in total immobility as measured by a TST in IMO+Veh (t=−2.394, df=8, p=0.044, Figure 7C] Figure 7M ) in the Amygdala and decreased levels in the mPFC (t=2.321, df=13, p=0.0371, Figure 7N ). The mRNA levels in females were upregulated in mPFC in the group IMO+Veh vs Control+Veh (t= 3,248 df=13 p=0.0064, Figure 7P ) and also in the group IMO+Cort vs Control+Veh in the Amygdala (t=2.579, df=14, p=0.0218, Figure 7S ). 
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Discussion
Here, we found that Ppm1f mRNA levels were significantly altered in the amygdala and mPFC after stress exposure in a mouse model. Furthermore, we demonstrate that the human blood mRNA level of PPM1F was significantly down-regulated in PTSD&Dep. Moreover, we show that a genetic variant in the 3′UTR of PPM1F, rs17759843, was significantly associated with PTSD&Dep and with mRNA levels of PPM1F in human blood as well as brain. Additionally, we found that one of the substrates of PPM1F, CAMK2G, had significantly down-regulated blood mRNA levels in PTSD&Dep, which is consistent with CAMK2 being a substrate of PPM1F. Consistently, Ppm1f protein levels and its colocalization with Camk2G were altered in the Amygdala and mPFC of male mice. Taken together, our findings suggest a novel and critical role of PPM1F in association with stress, anxiety, and depressive symptoms following trauma exposure.
PPM1F is a protein phosphatase and a member of the PP2C family of Ser/Thr protein phosphatases, which are negative regulators of stress response pathways. Calcium/ calmodulin-dependent protein kinase II gamma is one of the substrates of this phosphatase (27) (28) (29) . Interestingly, Ppm1f expression in mice was not altered at early time points after an aversive learning paradigm nor 1 day after IMO stress. A potential interpretation is that these changes in basal expression of Ppm1f require about a week to develop in mice. Also, it is possible that Ppm1f changes may not be related to fear learning, per se, or are not detected at the timing of the collection of the brain tissue in these experiments. In fact, our data suggest that it may be a marker of the chronic effects of prior trauma exposure.
Ppm1f specifically dephosphorylates Camk2 in rat neurons in vitro and in cells (30) . This results in an inactive form of CaMK2. CAMK2 is critical in serotonergic regulation of prefrontal cortex neuronal activity, which plays a major role in depression, suicide, anxiety, and schizophrenia (31) (32) (33) , and which may explain the neuropsychiatric behavioral patterns seen in CaMK2 knockout mice (34) . CaMK levels in the brain have been previously associated with anxiety (35) , depression (36) , and suicide victims (37) . Our present data suggests that PPM1F could be an upstream regulator -activated by traumatic stress -of CaMK, promoting the development of anxiety and depression-like symptoms. However, the consequences of regulation of PPM1F by stress could have broader implications than described here because of ubiquitous expression of PPM1F in the body and brain. For example, PTSD and depression have been associated with higher rates of coronary heart disease (38) (39) (40) and knowledge of the underlying mechanisms for this association is still limited. Since CaMK2 plays an important role in the development and progression of cardiovascular disease (41) (42) (43) , it is possible that the PPM1F/CaMK2 pathway may play a role in coronary diseases. Further study of PPM1F and CAMK2 may shed light on the mechanisms linking PTSD and depression to elevated risk for heart disease.
Using a different traumatic model than ours, previous studies have shown that exposing rats to a predator results in Amygdala upregulation but mPFC downregulation of phosphorylated Camk2 (pCamk2) one week later (44) . Consistently, we found significant changes in mRNA levels of CaMK2G in blood in human with PTSD&Dep symptoms and in the Amygdala of mice exposed to stress. Concordantly, we found that stress also regulated Camk2g protein in the mouse brain. Moreover, Ppm1f protein level in the Amygdala is regulated by stress in male mice suggesting that IMO alters Ppm1f levels. Regarding directionality, the Ppm1f mRNA level and Ppm1f protein level are in the same direction in the Amygdala but in opposite direction in the mPFC. Interestingly, Ppm1f/Camk2g colocalization is regulated by stress in the mouse brain. Thus, it is possible that PPM1F levels may be regulating CaMK2G after stress, promoting the development of depression and anxiety behaviors.
We also examined whether post-stress manipulation, i.e. systemic administration of corticosterone, may decrease the stress-related behavioral and molecular phenotypes (44) (45) (46) . Systemic corticosterone did not rescue the depressive-like phenotype elicited by IMO in male mice. However, corticosterone rescued the depressive-like behavior induced by IMO in female mice. EPM results showed that corticosterone rescued the anxiety-like behavior in male mice. In contrast, IMO did not induce an anxiety-like behavior in female mice. Analysis of the mRNA levels showed that corticosterone treatment shortly after stress rescued the genetic regulation of Ppm1f in the Amygdala and mPFC in males and in the mPFC in females. Thus, there appears to be relevant sex differences in Ppm1f regulation in the brain, acute exposure to traumatic stress and its treatment with corticosterone.
Our study should be interpreted in light of its limitations. First, the data obtained with IMO should be interpreted with caution. While most rodents develop anxiety and depression-like behavior after IMO, only a small percentage of the human population develops PTSD and/or depression. Second, rs17759843 is associated with blood expression of PPM1F in a sample of mostly European descent. rs17759843 has an MAF of 0.11 in Caucasians and 0.01 in African Americans per dbGAP HapMap populations. Whether this SNP is an eQTL in the African Americans remain to be determined, as we were likely underpowered to detect this relationship in our GTP dataset. Third, the Blood eQTL Browser provides statistics on bivariate association between rs17759843 and blood PPM1F expression. Hence, rs17759843 may be associated with PPM1F due to its linkage disequlibrium with other stronger eQTL SNPs for PPM1F. Fourth, we did not have access to human brain amygdala to examine association between rs17759843 and PPM1F expression. Fifth, we analyzed cases with significant current symptoms of PTSD&Dep but we did not have rigorous clinical assessment to determine if these cases had the diagnosis of PTSD or Major Depressive Disorder. Additionally, our cutoff score of 14 for the PSS and BDI, though based on published psychometric studies, may be lenient and thus could increase the risk of false positive. Sixth, the CHDWB replication sample uses the GAD-7, which is a good screening tool but could provide a false positive detection if not followed by an accurate clinical evaluation. Seventh, we found blood mRNA PPM1F level significantly down-regulated in cases with PTSD&Dep symptoms in the GTP sample and replicated this association in cases with anxiety symptoms in an independent CHDWB cohort. Our replication is only a quasireplication since anxiety symptoms can be PTSD symptoms but they can also be symptoms of generalized anxiety disorder or social anxiety disorder. Lastly, only a subset of GTP participants with genetic data had gene expression data. However, the two datasets are comparable as reflected by the distribution of their sex, BDI, and PSS scores ( Supplemental  Table S8 ).
In conclusion, mRNA and protein levels of phosphatase Ppm1f and Camk2g are regulated in the brain after exposure to traumatic stress in male and female mouse models and are associated with chronic anxiety-related (PTSD) and depression symptoms in traumatized humans. Because of the widespread expression of PPM1F in the body and brain, these changes in expression of PPM1F by stress may possibly have other pathophysiological implications that should be examined in future studies. Insights into the role of CAMK2 and PPM1F following trauma exposure may contribute to discovering novel approaches to treat or prevent the disabling conditions of PTSD and depression. Alternative Splicing were the more affected functions in these analysis. (B) IPA analysis showed more detailed functions altered after a single exposure to 2 hours stress immobilization. 
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Figure 4. A SNP within the PPM1F gene is associated with PTSD&Depression
The minor allele of rs17759843, a PPM1F 3′UTR SNP, is significantly associated with lower odds for PTSD & Depression after adjusting for gender and population substructure (OR=0.53; p=0.005; permuted p=0.046; n=2361). Each error bar is constructed using 1 standard error from the mean. 
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Author Manuscript male mice (A, B) . However, Corticosterone rescued the depressive-like behavior induced by IMO in female mice (C, D) *p≤0.05). EPM results showed that corticosterone rescued the anxiety-like behavior in male mice (E,F, I, J, *p≤0.05, **p≤0.01, ***p≤0.001 vs the other groups). In contrast, IMO did not induce an anxiety-like behavior in female mice (G, H, K) . The number of entries in closed arms was increased in the IMO+Veh vs Control+Veh group (L, *p≤0.05, ***p≤0.001 vs Control +Veh). Analysis of the mRNA levels in males showed that the IMO+Veh group presented
